Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) (PLATINUM QCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00824434
Recruitment Status : Completed
First Posted : January 16, 2009
Results First Posted : March 7, 2012
Last Update Posted : August 30, 2012
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
Compile acute (30-day) clinical outcomes data and 9-month angiographic and intravascular ultrasound (IVUS) data for the PROMUS Element™ Everolimus- Eluting Coronary Stent System in the treatment of patients with a single de novo atherosclerotic lesion

Condition or disease Intervention/treatment Phase
Atherosclerosis Coronary Artery Disease Device: PROMUS Element™ Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Study Start Date : March 2009
Actual Primary Completion Date : September 2009
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis
Drug Information available for: Everolimus

Arm Intervention/treatment
Experimental: Experimental Stent Device: PROMUS Element™
Drug eluting coronary stent system




Primary Outcome Measures :
  1. Cardiac Events (Composite) [ Time Frame: 30 days ]
    Percentage of patients who had a myocardial infarction, cardiac death, target lesion revascularization, or stent thrombosis (defined as definite or probable per the Academic Research Consortium [ARC] definitions); see below for definitions of individual components.


Secondary Outcome Measures :
  1. In-stent Late Loss [ Time Frame: 9 months ]
    In-stent late loss by quantitative coronary angiography in workhorse target lesions (visual reference vessel diameter [RVD] ≥2.5 mm and ≤4.25 mm and visual lesion length ≤24 mm)

  2. Occurance of Post-procedure Incomplete Stent Apposition [ Time Frame: Post-procedure ]
    Percentage of participants who experience incomplete stent apposition as determined immediately post-procedure by intravascular ultrasound

  3. Myocardial Infarction (MI) [ Time Frame: 12 months ]
    New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin >upper limit of normal(ULN); if no new Q-waves total CK levels >3×ULN (peri-percutaneous coronary intervention [PCI]) or >2×ULN (spontaneous) with elevated CK-MB or troponin >3×ULN (peri-PCI) or >2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin >5×ULN

  4. All-cause Mortality [ Time Frame: 12 months ]
  5. Target Lesion Revascularization (TLR) [ Time Frame: 30 Days ]
    Target lesion revascularization (TLR) is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.

  6. Target Lesion Revascularization (TLR) [ Time Frame: 12 Months ]
    Target lesion revascularization (TLR) is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.

  7. Target Vessel Revascularization (TVR) [ Time Frame: 30 Days ]
    Target vessel revascularization (TVR) is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.

  8. Target Vessel Revascularization (TVR) [ Time Frame: 12 months ]
    Target vessel revascularization (TVR) is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.

  9. Target Lesion Failure (TLF) [ Time Frame: 12 months ]
    Target lesion failure (TLF) is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.

  10. Target Vessel Failure (TVF) [ Time Frame: 12 months ]
    Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.

  11. Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition [ Time Frame: 24 hours ]
    DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

  12. Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition [ Time Frame: >24 hr-30 days ]
    DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

  13. Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition [ Time Frame: >30 days-1 year ]
    DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

  14. Clinical Procedural Success [ Time Frame: Duration of hospital stay (usually 1-2 days) ]
    Mean lesion diameter stenosis < 30% with TIMI 3 flow without the occurrence of in-hospital cardiac death, MI, or TVR

  15. Technical Success [ Time Frame: Acute-At time of index procedure ]
    Successful delivery and deployment of the study stent to the target lesion, without balloon rupture or embolization, summarized per stent.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient (or legal guardian) understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
  • Patient is eligible for percutaneous coronary intervention (PCI)
  • Patient has documented stable angina pectoris (Canadian Cardiovascular Society [CCS] Classification 1, 2, 3, or 4) or documented silent ischemia; or unstable angina pectoris (Braunwald Class IB-C, IIB-C, or IIIB-C)
  • Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
  • Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment
  • Patient is willing to comply with all specified follow-up evaluations

Angiographic Inclusion Criteria:

  • Target lesion must be a de novo lesion located in a native coronary artery with visually estimated diameter of >=2.25 mm and <=4.25 mm
  • Target lesion length must measure (by visual estimate) <=34 mm
  • Target lesion must be in a major coronary artery or branch with visually estimated stenosis >=50% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow >1.

Exclusion Criteria:

  • Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI)
  • Patient has had a known diagnosis of recent MI (within 30 days prior to the index procedure) and has elevated enzymes at the time of the index procedure as follows.

    • Patients are excluded if any of the following criteria are met at the time of the index procedure

      • If creatine kinase, MB band (CK-MB) >2× upper limit of normal (ULN), the patient is excluded regardless of the creatine kinase (CK) Total.
      • If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
    • If CK Total/CK-MB are not used and Troponin is, the patients are excluded if the following criterion is met at the time of the index procedure.

      • Troponin >1× ULN with at least one of the following.

        • Patient has ischemic symptoms and electrocardiogram (ECG) changes indicative of ongoing ischemia (e.g., >1mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
        • Development of pathological Q-waves in the ECG
        • Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

Note: For patients who have had a recent MI, CK Total/CK-MB (or Troponin if CK Total/CK-MB are not used) must be documented prior to enrolling the patient

  • Patient has received an organ transplant or is on a waiting list for an organ
  • transplant
  • Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
  • Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
  • Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
  • Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
  • Patient has a white blood cell (WBC) count <3,000 cells/mm3
  • Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
  • Patient is on dialysis or has known renal insufficiency (i.e., estimated creatinine clearance <50 mL/min by the Cockcroft Gault formula, ie [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dL)*72])
  • Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  • Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
  • Target vessel or side branch has been treated with any type of percutaneous coronary intervention (PCI; eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to the index procedure
  • Target vessel has been treated within 10 mm proximal or distal to the target lesion (by visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to the index procedure
  • Non-target vessel or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to the index procedure
  • Planned or actual target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement
  • Planned percutaneous coronary intervention or coronary artery bypass grafting after the index procedure
  • Patient previously treated at any time with coronary intravascular brachytherapy
  • Patient has a known allergy to the study stent system or protocol-required concomitant medications (e.g., stainless steel, platinum, cobalt, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated
  • Patient has active peptic ulcer or active gastrointestinal (GI) bleeding
  • Patient has one of the following:

    • Other serious medical illness (eg, cancer, congestive heart failure) that may reduce life expectancy to less than 24 months
    • Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)
    • Planned procedure that may cause non-compliance with the protocol or confound data interpretation
  • Patient is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
  • Patient intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
  • Known intention to procreate within 12 months after the index procedure
  • Female with positive pregnancy test within 7 days prior to the index procedure (a pregnancy test must be performed in women of child-bearing potential prior to enrollment), or lactating
  • Patient has more than 1 target lesion or more than 1 target lesion and 1 non-target lesion, identified during screening for intervention

Angiographic Exclusion Criteria:

  • Target lesion meets any of the following criteria:

    • Aorto-ostial location (i.e., lesion located within 5 mm of the ostium)
    • Left main location
    • Located within 5 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery
    • Located within a saphenous vein graft or an arterial graft
    • Can only be accessed via a saphenous vein graft or an arterial graft
    • Involves a side branch >=2.0 mm in diameter
    • Involves a clinically significant side branch <2.0 mm in diameter that has a clinically significant stenosis at the ostium
    • TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing
    • Excessive tortuosity proximal to or within the lesion
    • Extreme angulation proximal to or within the lesion
    • Target lesion and/or target vessel proximal to the target lesion is moderately to severely calcified
    • Restenotic from previous intervention
    • Thrombus, or possible thrombus, present in the target vessel
  • Patient has an additional clinically significant lesion(s) in the target vessel for which an intervention within 12 months after the index procedure is likely to be required

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00824434


Locations
Layout table for location information
Australia, New South Wales
St. Vincent's Hospital - Sydney
Darlinghurst, New South Wales, Australia, 2010
Royal North Shore Hospital
St Leonards, New South Wales, Australia, 2065
Australia, Victoria
Monash Medical Centre
Clayton, Victoria, Australia, 3168
St. Vincent Hospital (Melbourne)
Fitzroy, Victoria, Australia, 3065
Australia, Western Australia
Fremantle Hospital
Fremantle, Western Australia, Australia, 6160
Australia
Royal Adelaide Hospital
Adelaide, Australia, 5000
The Prince Charles Hospital
Brisbane, Australia, 4032
Liverpool Hospital
Liverpool, Australia, 2170
Sir Charles Gairdner Hospital
Perth, Australia, 6009
Malaysia
Institut Jantung Negara
Kuala Lumpur, Malaysia, 50400
New Zealand
Middlemore Hospital
Otahuhu, Auckland, New Zealand
North Shore Hospital
Takapuna, Auckland, New Zealand, 0622
Christchurch Hospital
Christchurch, New Zealand, 8001
Dunedin Hospital
Dunedin, New Zealand, 9001
Wellington Hospital
Wellington, New Zealand
Singapore
National University Hospital, Singapore
Singapore, Singapore, 119074
National Heart Centre Singapore
Singapore, Singapore, 168752
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Principal Investigator: Ian T. Meredith, MBBS Monash Medical Centre

Publications of Results:
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT00824434     History of Changes
Other Study ID Numbers: S2051
First Posted: January 16, 2009    Key Record Dates
Results First Posted: March 7, 2012
Last Update Posted: August 30, 2012
Last Verified: August 2012
Keywords provided by Boston Scientific Corporation:
Atherosclerosis
Coronary Artery Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Atherosclerosis
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Everolimus
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs